Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Lays Foundation Stone of 6 new facilities at AIIMS Bhopal and inaugurates a slew of facilities in Madhya Pradesh
Subscribe To Our Newsletter & Stay Updated
